Notice of Interim Results

RNS Number : 0839R

Destiny Pharma PLC

19 September 2017

 

Destiny Pharma plc

("Destiny" or "the Company")

Notice of Interim Results

Brighton, United Kingdom - 19 September, 2017 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), will announce its maiden interim results for the six months ending 30 June 2017 on Wednesday 27 September 2017.

A meeting for analysts will be held at 11:00am BST on Wednesday 27 September at the offices of FTI Consulting, 200 Aldersgate Street, London EC1A 4HD.

Dial-in details for the live conference call will be made available on the Company's website.

For further information, please contact:

Destiny Pharma

Neil Clark, CEO

Simon Sacerdoti, CFO

[e-mail]

[phone]

FTI Consulting

Simon Conway / Victoria Foster Mitchell / Hanna Skeppner

[e-mail] 

[phone]

Cantor Fitzgerald Europe (Nominated Adviser and Broker)

Philip Davies / Will Goode, Corporate Finance

[phone]

About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the WHO and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com.

 

END

 

 

NORSFEFMAFWSESU